Goldman Sachs Group Inc. downgraded Seattle Genetics, Inc. (NASDAQ:SGEN) to Sell in a report released today.
- Updated: September 15, 2016
Goldman Sachs Group Inc. has downgraded Seattle Genetics, Inc.(NASDAQ:SGEN) to Sell in a statement released on 9/16/2016.
Yesterday Seattle Genetics, Inc. (NASDAQ:SGEN) traded 0.06% lower at $53.59. SGEN’s 50-day moving average is $47.22 and its 200-day average is $40.11. With the last stock price close up 34.70% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the same time. Volume of trade was was down over the average, with 250,225 shares of SGEN changing hands under the typical 768,518 shares..
Seattle Genetics, Inc. has a 52 week low of $26.02 and a 52 week high of $55.19 and has a market capitalization of $0.0.
Brief Synopsis On Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, and which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.